Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 2, 1996, Pages 387-392

  Oethinger, M ^a,c   Conrad, S ^a   Kaifel, K ^a   Cometta, A ^b   Bille, J ^b   Klotz, G ^a   Glauser, M P ^b   Marre, R ^a   Kern, W V ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TETRACYCLINE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CANCER CENTER; CANCER PATIENT; CLINICAL ARTICLE; ESCHERICHIA COLI; GENETIC VARIABILITY; GENOTYPE; HUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RANDOM AMPLIFIED POLYMORPHIC DNA;

EID: 0030051165     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.2.387     Document Type: Article

References (38)

1. Acar, J. F., T. F. O'Brien, F. W. Goldstein, and R. N. Jones. 1993 The epidemiology of bacterial resistance to quinolones. Drugs 45(Suppl 3):24-28
2. Arbeit, R. D., M. Arthur, R. Dunn, C. Kim, R. K. Selander, and R. Goldstein. 1990 Resolution of recent evolutionary divergence among Escherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology. J Infect. Dis. 161:230-235.
3. Ball, P. 1995. Is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis? Clin. Infect. Dis. 20:561-563. (Editorial response.)
4. Bauernfeind, A., M. Abele-Horn, P. Emmerling, and R. Jungwirth. 1994. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J. Antimicrob. Chemother 34:1075-1076.
5. Berg, D. E., N. S. Akopyants, and D. Kersulyte. 1994. Fingerprinting microbial genomes using the RAPD or AP-PCR method. Methods Mol. Cell. Biol. 5:13-24.
6. Böhm, H., and H. Karch. 1992. DNA fingerprinting of Escherichia coli O157:H7 strains by pulsed-field gel electrophoresis. J Clin. Microbiol 30: 2169-2172
7. Carratalá, J., A. Fernández-Sevilla, F. Tubau, M. Callis, and F. Gudiol. 1995. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin. Infect. Dis. 20:557-560.
8. Cometta, A., T. Calandra, J. Bille, and M. P. Glauser. 1994 Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N. Engl. J. Med. 330:1240-1241.
9. Cometta, A., S. Zinner, R. De Bock, T. Calandra, H. Gaya, J. Klastersky, J. Langenaeken, M. Paesmans, C. Viscoli, M. P. Glauser, and the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. 1995. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer Antimicrob. Agents Chemother. 39: 445-452.
10. Cookson, B., A. P. Johnson, B. Azadian, J. Paul, G. Hutchinson, M. Kaufmann, N. Woodford, M. Malde, B. Walsh, A. Yousif, and J. Selkon. 1995. International inter- and intrahospital patient spread of a multiple antibiotic-resistant strain of Klebsiella pneumoniae J. Infect. Dis. 171:511-513.
11. Courvalin, P. 1990. Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob. Agents Chemother. 34:681-684.
12. EORTC International Antimicrobial Therapy Cooperative Group and GIMEMA Infection Program. 1995. Meropenem versus ceftazidime plus amikacin as empirical therapy for fever in cancer patients with granulocytopenia, abstr. 1083. Program and Abstracts of the 19th International Congress on Chemotherapy.
13. Farmer, J. J., III, and M. T. Kelly. 1991 Enterobacteriaceae. p. 360-383. In A. Balows, J. H. Hausler, K L Herrmann, H. D. Isenberg, and H. J. Shadomy (ed ), Manual of clinical microbiology. American Society for Microbiology, Washington, D C.
14. Grundmann, H., C. Schneider, D. Hartung, F. D. Daschner, and T. L. Pitt. 1995. Discriminatory power of three DNA-based typing techniques for Pseudomonas aeruginosa. J. Clin. Microbiol 33:528-534.
15. Heisig, P., H. Scnedlitzky, and H. Falkenstein-Paul. 1993. Mutations in the gyrA gene of a high-level fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother 37:696-701.
16. Heisig, P., and R. Tschorny. 1994 Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother. 38:1284-1291
17. Hibbert-Rogers, L. C. F., J. Heritage, D. M. Gascoyne-Binzi, P. M. Hawkey, N. Todd, I. J. Lewis, and C. Bailey. 1995 Molecular epidemiology of ceftazidime-resistant Enterobacteriaceae from patients on a paediatric ward. J. Antimicrob. Chemother. 36:65-82
18. Kern, W. V., E. Andriof, M. Oethinger, P. Kern, J. Hacker, and R. Marre. 1994 Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681-687.
19. Kresken, M., D. Hafner, H. Mittermayer, L. Verbist, E. Bergogne Berezin, H. Giamarellou, S. Esposito, B. van Klingeren, F. H. Kayser, and D. S. Reeves. 1994 Prevalence of fluoroquinolone resistance in Europe. Infection 22(Suppl 2):S90-S98.
20. Kresken, M., and B. Wiedemann. 1988. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin Antimicrob. Agents Chemother. 32:1285-1288.
21. Linhardt, F., W. Ziebuhr, P. Meyer, W. Witte, and J. Hacker. 1992. Pulsed-field gel electrophoresis of genomic restriction fragments as a tool for the epidemiological analysis of Staphylococcus aureus and coagulase-negative staphylococci. FEMS Microbiol. Lett. 95:181-186
22. López-Brea, M., R. Arranz, N. Somolinos, M. C. Del Rev, and M. L. Jimenez. 1992 Escherichia coli clinical isolates resistant to fluoroquinolones from immunocompromised patients, abstr. 634. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C
23. Madico, G., N. S. Akopyants, and D. E. Berg. 1995 Arbitrarily primed PCR DNA fingerprinting of Escherichia coli O157:H7 strains by using templates from boiled cultures J. Clin Microbiol 33:1534-1536.
24. Maslow, J. N., A. M. Slutsky, and R. D. Arbeit. 1993 Application of pulsed-field gel electrophoresis to molecular epidemiology, p. 563-572. In D H. Persing, T. F. Smith, F C. Tenover, and T. J. White (ed ), Diagnostic molecular microbiology: principles and applications. American Society for Microbiology, Washington, D.C.
25. National Committee for Clinical Laboratory Standards. 1994 Performance standards for antimicrobial susceptibility testing. Fifth informational supplement. NCCLS document M100-S5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. Oethinger, M., S. Conrad, K. Häussler, A. Cometta, J. Bille, T. Calandra, M. P. Glauser, R. Marre, and W. V. Kern. 1995. Fluoroquinolone-resistant Escherichia coli isolates from European cancer centers: genotypes and phenotypes, abstr. 2319. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
27. Oram, M., and L. M. Fisher. 1991. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob. Agents Chemother 35:387-389.
28. Ouabdesselam, S., D. C. Hooper, J. Tankovic, and C. J. Soussy. 1995. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob. Agents Chemother. 39:1667-1670
29. Peña, C., J. M. Albareda, R. Pallares, M. Pujol, F. Tubau, and J. Ariza. 1995. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob. Agents Chemother. 39:520-524.
30. Richard, P., M. H. Delangle, D. Merrien, S. Barille, A. Reynaud, C. Minozzi, and H. Richet. 1994. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin. Infect. Dis. 19:54-59.
31. Römling, U., D. Grothues, T. Heuer, and B. Tümmler. 1992. Physical genome analysis of bacteria. Electrophoresis 13:626-631
32. Struelens, M. J., R. Bax, A. Deplano, W. G. V. Quint, and A. van Belkum. 1993. Concordant clonal delineation of methicillin-resistant Staphylococcus aureus by macrorestriction analysis and polymerase chain reaction genome fingerprinting. J. Clin. Microbiol. 31:1964-1970.
33. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239
34. Van Belkum, A. 1994. DNA fingerprinting of medically important microorganisms by use of PCR. Clin. Microbiol. Rev. 7:174-184
35. Vila, J., J. Ruiz, F. Marco, A. Barcelo, P. Goñi, E. Giralt, and T. Jimenez de Anta. 1994. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs Antimicrob. Agents Chemother. 38:2477-2479.
36. Wang, G., T. S. Whittam, C. M. Berg, and D. E. Berg. 1993 RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains. Nucleic Acids Res. 21:5930-5933
37. Wendt, C., R. Hollis, M. Pfaller, R. Wenzel, and L. Herwaldt. 1995. Molecular epidemiology of bacteremia due to Escherichia coli, abstr. 1106. In Program and abstracts of the 7th European Congress on Clinical Microbiology and Infectious Diseases.
38. Wolfson, J., and D. C. Hooper. 1989. Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev. 2:378-424.